Inhibition of RANKL-induced osteoclastogenesis through the suppression of the ERK signaling pathway by astragaloside IV and attenuation of titanium-particle-induced osteolysis.

International Journal of Molecular Medicine
Mingjun LiMingzhi Zhang

Abstract

Astragaloside IV (AS-IV) is a natural plant extract that enhances osteoblast activity, and therefore, has the potential to treat osteoclast‑related diseases. Such diseases include osteoporosis, periodontal disease, rheumatoid arthritis and aseptic prosthesis loosening. However, data associating the effects of AS‑IV on osteoclasts are limited. The aim of the present study was to assess the effect of AS‑IV on osteoclasts in vitro and in vivo. The in vitro studies demonstrated that AS‑IV exerts potent inhibitory effects on the ligand of the receptor activator of nuclear factor‑κB‑induced osteoclastogenesis and revealed the mechanism of action of AS‑IV, which inhibited osteoclastogenesis by suppression of the extracellular signal‑regulated kinase signaling pathway. The in vivo studies proved that AS‑IV attenuated titanium particle‑induced osteolysis in a mouse calvarial model. Collectively, the findings of the study suggest that AS‑IV is a potential natural agent for the treatment of osteoclast-related diseases.

References

Nov 1, 1994·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·J A Kanis
Nov 14, 1997·Nature Medicine·V IotsovaR Bravo
Feb 7, 1998·Genes & Development·G FranzosoU Siebenlist
Sep 1, 2000·Science·G A Rodan, T J Martin
May 16, 2003·Nature·William J BoyleDavid L Lacey
Aug 27, 2005·The Journal of Biological Chemistry·Paula MonjeJ Silvio Gutkind
Jun 17, 2006·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·Weiping RenPaul H Wooley
Jul 13, 2006·Annals of the New York Academy of Sciences·M Neale Weitzmann, Roberto Pacifici
Sep 19, 2006·Clinical Orthopaedics and Related Research·P Edward PurdueThomas P Sculco
Nov 14, 2006·Bone·Masataka Asagiri, Hiroshi Takayanagi
Oct 24, 2007·Calcified Tissue International·Christian WedemeyerGuido Saxler
Nov 7, 2008·Clinical and Experimental Pharmacology & Physiology·Jiong-Yu HuYue-Sheng Huang
Jan 21, 2009·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·P J MeunierJ Y Reginster
Aug 13, 2009·The New England Journal of Medicine·Steven R CummingsUNKNOWN FREEDOM Trial
May 27, 2010·The Journal of Biological Chemistry·Liza J Raggatt, Nicola C Partridge
Oct 5, 2010·International Journal of Toxicology·Wan XuyingZhang Weidong
Jun 2, 2012·The International Journal of Biochemistry & Cell Biology·A QinM H Zheng
Feb 14, 2013·Expert Review of Pharmacoeconomics & Outcomes Research·Mickaël HiligsmannJean-Yves Reginster
Feb 20, 2013·JAMA Internal Medicine·Maria C S InacioArt Sedrakyan
Jul 16, 2013·Evidence-based Complementary and Alternative Medicine : ECAM·Shufeng TanNiansong Wang
Sep 13, 2013·Journal of Traditional Chinese Medicine = Chung I Tsa Chih Ying Wen Pan·Shuang RenPing Liu
May 17, 2014·Arquivos brasileiros de endocrinologia e metabologia·Sergio Setsuo Maeda, Marise Lazaretti-Castro
Jun 14, 2014·International Journal of Molecular Sciences·Sang-Hyun LeeHae-Dong Jang
Oct 22, 2014·International Journal of Molecular Sciences·Young Woo KimShin-Yoon Kim

❮ Previous
Next ❯

Citations

Oct 12, 2018·British Journal of Pharmacology·Yunxia WangRong Qi
Jul 19, 2019·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Qun DingShuanrang Jing
Jul 26, 2017·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Xiao ChenJiacan Su
Apr 24, 2020·Journal of Biomedical Materials Research. Part a·Xiang WeiHuaqiang Zhao
Mar 23, 2017·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Wei ZhouXingyu Zhang
Dec 30, 2016·Drug Metabolism Reviews·Dragos ApostuSimion Bran

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angelman Syndrome

Angelman syndrome is a neurogenetic imprinting disorder caused by loss of the maternally inherited UBE3A gene and is characterized by generalized epilepsy, limited expressive speech, sleep dysfunction, and movement disorders. Here is the latest research.